Bank Julius Baer & Co. Ltd Zurich Takes Position in Becton, Dickinson and Company $BDX

Bank Julius Baer & Co. Ltd Zurich purchased a new position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 531 shares of the medical instruments supplier’s stock, valued at approximately $91,000.

A number of other hedge funds also recently bought and sold shares of BDX. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Avantax Advisory Services Inc. boosted its holdings in shares of Becton, Dickinson and Company by 30.5% in the first quarter. Avantax Advisory Services Inc. now owns 24,219 shares of the medical instruments supplier’s stock worth $5,548,000 after buying an additional 5,659 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Becton, Dickinson and Company by 18.8% in the first quarter. Cetera Investment Advisers now owns 78,838 shares of the medical instruments supplier’s stock worth $18,058,000 after buying an additional 12,485 shares during the last quarter. one8zero8 LLC bought a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $202,000. Finally, LPL Financial LLC raised its position in Becton, Dickinson and Company by 20.2% in the first quarter. LPL Financial LLC now owns 358,539 shares of the medical instruments supplier’s stock worth $82,127,000 after acquiring an additional 60,253 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,249 shares of company stock worth $231,358 over the last three months. 0.36% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BDX shares. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus reduced their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Trading Down 0.7%

Becton, Dickinson and Company stock opened at $191.32 on Tuesday. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The firm’s 50 day moving average price is $186.94 and its 200-day moving average price is $182.60. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market cap of $54.84 billion, a P/E ratio of 34.41, a PEG ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a $1.05 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.